NCT00005005View on ClinicalTrials.gov

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Osteoporosis
Interventions
DRUG

PTH

DRUG

Alendronate

Trial Locations (4)

10032

Columbia University, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

55415

University of Minnesota, Minneapolis

04401

Maine Center for Osteoporosis, Bangor

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Dennis Black

OTHER

NCT00005005 - PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis | Biotech Hunter | Biotech Hunter